Volitionrx (VNRX) EBITDA Margin (2019 - 2025)
Volitionrx (VNRX) has disclosed EBITDA Margin for 9 consecutive years, with 1273.91% as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBITDA Margin fell 726.0% year-over-year to 1273.91%, compared with a TTM value of 2135.89% through Sep 2025, up 22055.0%, and an annual FY2024 reading of 2198.3%, up 240123.0% over the prior year.
- EBITDA Margin was 1273.91% for Q3 2025 at Volitionrx, up from 2813.31% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1266.66% in Q3 2024 and bottomed at 61692.56% in Q4 2021.
- Average EBITDA Margin over 5 years is 12159.44%, with a median of 5097.66% recorded in 2023.
- The sharpest move saw EBITDA Margin skyrocketed 105555788bps in 2021, then crashed -103540bps in 2025.
- Year by year, EBITDA Margin stood at 61692.56% in 2021, then surged by 90bps to 6201.93% in 2022, then surged by 42bps to 3605.06% in 2023, then rose by 19bps to 2928.08% in 2024, then skyrocketed by 56bps to 1273.91% in 2025.
- Business Quant data shows EBITDA Margin for VNRX at 1273.91% in Q3 2025, 2813.31% in Q2 2025, and 2325.85% in Q1 2025.